This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue


Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.



Dose and Schedule1

  • Each dose of BOOSTRIX is administered as a 0.5-mL injection
  • An initial dose of BOOSTRIX is administered 5 years or more after the last dose of the Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) series or 5 years or more after a dose of Tetanus and Diphtheria Toxoids Adsorbed (Td)
  • BOOSTRIX may be administered as an additional dose 9 years or more after the initial dose of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap)
  • BOOSTRIX may be administered for tetanus prophylaxis for wound management. For management of a tetanus-prone wound, a dose of BOOSTRIX may be administered if at least 5 years have elapsed since previous receipt of a tetanus toxoid-containing vaccine

Dosage Forms and Strengths1

  • BOOSTRIX is available as single-dose vials and single-dose prefilled syringes containing a 0.5-mL suspension for injection

BOOSTRIX comes with a 2D barcode

  • 2D barcodes contain the vaccine name, manufacturer, National Drug Code (NDC) numbers, lot number, and expiration date
  • With 2D barcodes, you can update your inventory management system, patient records, and vaccination reports automatically, reducing the need for manual data entry if you have the correct scanner, hardware, and software

Preparation for Administration1

  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use the vaccine if either of these conditions exist. Shake vigorously to obtain a homogeneous, turbid, white suspension before administration. Do not use if resuspension does not occur with vigorous shaking
  • For the prefilled syringes, attach a sterile needle and administer intramuscularly
  • For the vials, use a sterile needle and sterile syringe to withdraw the 0.5-mL dose and administer intramuscularly. Changing needles between drawing vaccine from a vial and injecting it into a recipient is not necessary unless the needle has been damaged or contaminated

CPT® code3 : 90715

BOOSTRIX and Tip-Lok are registered trademarks of the GSK group of companies.
Luer-Lok is a registered trademark of Becton, Dickinson and Company.
CPT is a registered trademark of the American Medical Association.

BOOSTRIX may be administered as an additional dose 9 years or more after the initial dose of Tdap


  1. Prescribing Information for BOOSTRIX.
  2. Prescribing Information for Adacel.
  3. American Medical Association. 2013 Current Procedural Terminology (CPT) Professional Edition. 4th rev ed. Chicago, IL: American Medical Association; 2012.